Peptide Comparison
Tesamorelin vs Hexarelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tesamorelin has stronger documented evidence (FDA-Approved) than Hexarelin (Phase 2 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Hexarelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Tesamorelin | Hexarelin | |
|---|---|---|
| Class | GHRH analog (FDA-approved) | GHRP; potent ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion | GHS-R1a agonist; more potent GH release than other GHRPs |
| Route | SC injection | SC / Intranasal |
| Half-life | ~26 min | ~1 hr |
| Dosage (research) | 2 mg SC daily (FDA label) | 100-200 mcg SC 1-2x daily (short cycles) |
| Evidence tier | FDA-Approved | Phase 2 (not approved) |
| Research depth | 165 indexed | 196 indexed |
| Availability | Prescription | Research Chemical |
| Reported risks | Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 | Cortisol/prolactin elevation; pituitary desensitization |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Tesamorelin or Hexarelin?
Tesamorelin has stronger documented evidence (FDA-Approved) than Hexarelin (Phase 2 (not approved)) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Hexarelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Tesamorelin and Hexarelin?
Tesamorelin is classed as GHRH analog (FDA-approved); Hexarelin is classed as GHRP; potent ghrelin receptor agonist. Reported mechanism: Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion; Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs. Reported half-life: Tesamorelin, ~26 min; Hexarelin, ~1 hr. Routes in published studies: Tesamorelin, SC injection; Hexarelin, SC / Intranasal.
Which has stronger evidence, Tesamorelin or Hexarelin?
Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 165 indexed studies. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 196 indexed studies.
Which is more accessible, Tesamorelin or Hexarelin?
Tesamorelin is FDA-approved and Hexarelin is not. Catalog status: Tesamorelin, Prescription; Hexarelin, Research Chemical.
Are Tesamorelin and Hexarelin ever combined?
Tesamorelin and Hexarelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…